Pigmented progressive purpuric dermatosis - Pigmented Onitẹsiwaju Purpuric Dermatosishttps://en.wikipedia.org/wiki/Pigmented_purpuric_dermatosis
Pigmented Onitẹsiwaju Purpuric Dermatosis (Pigmented progressive purpuric dermatosis) n tọka si awọn ipo awọ ti ko ni irẹwẹsi nipasẹ awọn eruptions awọ ara purpuric. Iwọn ti ọgbẹ naa jẹ lati 0.3 si 1 cm ati pe a maa n rii nigbagbogbo ni awọn igun isalẹ. Ipara cortisone yoo ṣe iranlọwọ fun irẹwẹsi ati imudarasi discoloration ti awọ ara. pigmented onitẹsiwaju purpuric dermatosis (pigmented progressive purpuric dermatosis) fa ko si awọn aami aisan miiran lẹgbẹẹ awọ ara. Awọn ọgbẹ jẹ loorekoore julọ lori awọn ẹsẹ isalẹ, ṣugbọn o le waye nibikibi lori ara, pẹlu ọwọ, apá, torso ati paapaa ọrun.

Itọju - Oògùn OTC
ikunra sitẹriọdu OTC
#Hydrocortisone ointment
#Hydrocortisone cream
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
  • Schamberg disease - akọ 26 kan ti o jẹ ọmọ ọdun 26 pẹlu patch ti pigmentation asymptomatic ati telangiectasia lori ẹsẹ.
    References Pigmented Purpuric Dermatoses: A Complete Narrative Review 34070260 
    NIH
    Pigmented purpuric dermatoses (PPD) jẹ ẹgbẹ kan ti awọn ipo awọ ara ti a samisi nipasẹ awọn agbegbe kekere ti ẹjẹ labẹ awọ ara nitori iredodo capillary. PPD maa n bẹrẹ bi pupa si awọn aaye eleyi ti o yipada ni goolu-brown bi hemosiderin ti tun pada.
    Pigmented purpuric dermatoses (PPD) include several skin diseases characterized by multiple petechial hemorrhage as consequence of capillaritis. PPD generally present with red to purple macules that progressively evolve to golden-brown color as the hemosiderin is reabsorbed.
     Schamberg Disease 32809367 
    NIH
    Schamberg disease jẹ oriṣi ti o wọpọ julọ ti pigmented purpuric dermatoses (PPDs) , eyiti o jẹ awọn ipo awọ-ara onibaje ti o jẹ ami pupa tabi awọn aaye elesè-awọ-awọ-awọ-awọ-awọ ti o pọ si (awọn abulẹ ti brown, pupa, tabi ofeefee) . Awọn PPD ti pin si awọn oriṣi marun: Schamberg's purpura, Majocchi purpura, lichen aureus, Gougerot-Blum purpura, eczematoid-like purpura of Doucas and Kapetanakis. Schamberg disease (SD) tun mọ bi progressive pigmentary dermatosis of Schamberg, purpura pigmentosa progressiva, Schamberg's purpura. O maa n kan awọn ọkunrin ati pe o han ni awọn ẹsẹ isalẹ, ṣugbọn o tun le waye lori itan, awọn apọju, ẹhin mọto, tabi awọn apa.
    Schamberg disease represents the most common type of pigmented purpuric dermatoses (PPDs), a chronic, benign, cutaneous eruptions characterized by petechiae, purpura, and increased skin pigmentation (brown, red, or yellow patchy). The PPDs are grouped into five clinical entities: Schamberg's purpura, Majocchi purpura, lichen aureus, Gougerot-Blum purpura and, eczematoid-like purpura of Doucas and Kapetanakis. Schamber disease (SD) has also been called: progressive pigmentary dermatosis of Schamberg, purpura pigmentosa progressive and, Schamberg's purpura. It is commonly seen in males and mainly affects the tibial regions, and could involve thighs, buttocks, trunk, or upper extremities.
     Characteristics and Clinical Manifestations of Pigmented Purpuric Dermatosis 26273156 
    NIH
    Alaye lori awọn alaisan 113 pẹlu PPD ni a ṣe atupale, pẹlu 38 ti o gba biopsy awọ ara fun iwadi yii. Iru ile-iwosan ti o wọpọ julọ ni arun Schamberg (60. 5%) . Awọn ipo miiran pẹlu PPD jẹ haipatensonu (15. 8%) , diabetes (10. 5%) , ati awọn miiran. Awọn itan-akọọlẹ oogun ṣe afihan awọn statins (13. 2%) , beta blockers (10. 5%) , ati awọn miiran. Awọn okunfa to ṣeeṣe ti o sopọ mọ PPD pẹlu ikolu atẹgun oke to ṣẹṣẹ (5. 3%) , iduro gigun ti o yori si titẹ orthostatic giga (2. 6%) , ati adaṣe ti o nira (2. 6%) . A ṣe itọju itọju si awọn alaisan 36 (94. 7%) - oral antihistamines, pentoxifylline, topical steroids, and/or phototherapy.
    Information on 113 patients with PPD was analyzed, and 38 subjects with skin biopsy were included for this study. Schamberg's disease was the most frequent clinical type (60.5%). Concomitant diseases included hypertension (15.8%), diabetes (10.5%), and others. Associated medication histories included statins (13.2%), beta blockers (10.5%), and others. Possibly associated etiologic factors were recent upper respiratory infection (5.3%), high orthostatic pressure due to prolonged standing (2.6%), and strenuous exercise (2.6%). A total of 36 patients (94.7%) were treated with one or more treatment methods, including oral antihistamines, pentoxifylline, topical steroids, and/or phototherapy.